Disc Medicine to Present Multiple Studies at EHA 2024 Congress
Disc Medicine, Inc., a clinical-stage biopharmaceutical company listed on NASDAQ as IRON, has announced its plans to present data from various ongoing programs in its hematology portfolio at the European Hematology Association (EHA) 2024 Congress. The event will take place in Madrid, Spain, from June 13 to June 16, 2024. Disc Medicine is focused on developing innovative treatments for serious hematologic diseases, and this upcoming presentation underscores the company's ongoing research and development efforts.
John Quisel, the President and CEO of Disc Medicine, expressed enthusiasm about the company's participation at the EHA Congress. Quisel highlighted that Disc Medicine would present four posters demonstrating the potential of their three clinical-stage drugs. The presentations will cover detailed analyses from the AURORA study, a comprehensive data set for DISC-0974 in myelofibrosis (MF) anemia, and initial data from DISC-3405 in healthy volunteers.
On June 14th at 8:00 am ET, the management team of Disc Medicine will host a call to review the presented data. The full abstracts are now accessible through the EHA conference website, and while the abstracts contain previously presented data, new data is expected to be shared during the conference.
The presentations at the EHA Congress are as follows:
1. Abstract Number: P1575
- Title: Topline Results of The AURORA Trial: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Bitopertin in Erythropoietic Protoporphyria
- Date / Time: Friday, June 14, 6:00 pm CEST / 12 pm ET
- Presenter: Amy Dickey, M.D., MSc
2. Abstract Number: P1569
- Title: Results from the BEACON Trial: A Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria
- Date / Time: Friday, June 14, 6:00 pm CEST / 12 pm ET
- Presenter: Gayle Ross, M.D.
3. Abstract Number: P1059
- Title: A Phase 1b Trial of DISC-0974, An Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
- Date / Time: Friday, June 14, 6:00 pm CEST / 12 pm ET
- Presenting Author: Naseema Gangat, M.B.B.S.
4. Abstract Number: P1563
- Title: Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6
- Date / Time: Friday, June 14, 6:00 pm CEST / 12 pm ET
- Presenter: Guowen Liu, Ph.D.
Disc Medicine is dedicated to discovering, developing, and commercializing novel treatments addressing a broad range of hematologic diseases. The company's portfolio includes potentially groundbreaking therapeutic candidates that target fundamental biological pathways involved in red blood cell biology, specifically heme biosynthesis and iron homeostasis.
The data to be presented at the EHA Congress is anticipated to provide significant insights into the efficacy and safety of Disc Medicine's pipeline drugs, offering hope for future therapies targeting serious blood disorders.
The company invites interested parties to join the review call on June 14th to gain further insights into the presented data. The call registration details can be found on the Events and Presentations page of Disc’s website.
Disc Medicine continues to forge ahead in its mission to develop innovative treatments for hematologic conditions, and the upcoming presentations at the EHA Congress will be a pivotal moment to share their progress with the scientific community.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
